Clinical trials: Idiopathic Pulmonary Fibrosis (IPF), open to volunteers
Rheumatoid Arthritis, Interstitial Lung Disease
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA).
- Trial name
- RAPID (NCT03297775)
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- University of Colorado, Denver
Pulmonary Fibrosis, Lung Fibrosis
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
- Conditions
- Pulmonary Fibrosis, Lung Fibrosis, Idiopathic Pulmonary Fibrosis, FAP
- Trial name
- FAPIPET (NCT06189820)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 70 people
- Sponsor
- Erasme University Hospital
Idiopathic Pulmonary Fibrosis (IPF)
Evaluating the Efficacy and Safety of of HSK50042 in People With Idiopathic Pulmonary Fibrosis
This study is open to adults with idiopathic pulmonary fibrosis who are at least 40 years old. The main objective is to evaluate of the efficacy and the secondary objective is to evaluate the safety and pharmacokinetic.
- Trial name
- IPF (NCT07728721)
- Testing
- HSK50042 dose 1, HSK50042 dose 2, HSK50042 dose 3
- Volunteers
- 175 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Diffuse Parenchymal Lung Diseases
Prospective Data Collection of Patients With Diffuse Parenchymal Lung Diseases
The purpose of this study is to generate a prospective database of all patients evaluated for diffuse parenchymal lung diseases to provide much needed data on the various disease aetiologies, incidence and prevalence rates…
- Trial name
- NCT01600378
- Where
- Singapore
- Volunteers
- 500 people
- Sponsor
- Singapore General Hospital
Idiopathic Pulmonary Fibrosis(IPF)
CAR-DC for End-Stage IPF
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fatal interstitial lung disease characterized by irreversible scarring, leading to respiratory failure.
- Trial name
- NCT07329959
- Testing
- Leukapheresis, CAR-DC
- Volunteers
- 8 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Idiopathic Pulmonary Fibrosis
Dose-Escalation Study of Artesunate Patients With IPF
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive fibrotic lung disease resulting in increasing shortness of breath, cough, and low oxygen levels as a result of lung tissue scarring .
- Trial name
- SAFE-IPF (NCT05988463)
- Testing
- Artesuante
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Joseph C. Wu
Idiopathic Pulmonary Fibrosis (IPF)
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
This study is a multicentre, randomised, double-blind, placebo-controlled, adaptive design clinical trial to evaluate the efficacy and safety of TDI01 suspension in the treatment of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07464912
- Testing
- TDI01
- Where
- China
- Volunteers
- 508 people
- Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
Idiopathic Pulmonary Fibrosis (IPF)
Motivational Interviewing Program on the Self-Care in Idiopathic Pulmonary Fibrosis
A specific tool developed to measure self-care in patients with Idiopathic Pulmonary Fibrosis (IPF) is the SC-IPFI, which is an adaptation of an already validated instrument for COPD.
- Trial name
- MI-IPF (NCT07179562)
- Testing
- "motivational interviewing"
- Volunteers
- 124 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Idiopathic Pulmonary Fibrosis
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT07687459
- Testing
- INS018_055 tablets
- Where
- 47 sites in China
- Volunteers
- 320 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Idiopathic Pulmonary Fibrosis
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier.
- Trial name
- MAVRIC (NCT07520110)
- Testing
- Metformin
- Where
- 15 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Massachusetts, Worcester
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue.
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial
- Trial name
- NCT06325696
- Testing
- hymecromone
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
IPF, Idiopathic Pulmonary Fibrosis
SB17170 Phase 2 Trial in IPF Patients
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by…
- Conditions
- IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- Trial name
- NCT06747923
- Testing
- SB17170
- Where
- 5 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- SPARK Biopharma
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
- Trial name
- TETON-OLE (NCT04905693)
- Testing
- Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
- Where
- 192 sites in United States, Argentina and 16 more
- Volunteers
- 1,850 people
- Sponsor
- United Therapeutics
Idiopathic Pulmonary Fibrosis (IPF)
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT07447102
- Testing
- BC006
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
Fibrosis, Pulmonary
HOXB7 and Linked Tissue and Blood Biomarkers in the Lungs of Patients With Pulmonary Fibrosis
This pilot, multicenter, interventional study investigates the expression of HOXB7 and its associated molecular pathway in lung tissue and blood-derived exosomes from patients with pulmonary fibrosis (PF), including idiopathic…
- Trial name
- HOGWARTS (NCT07373288)
- Testing
- Biopsy
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- University of Modena and Reggio Emilia
Idiopathic Pulmonary Fibrosis (IPF)
Nintedanib With or Without Dextromethorphan in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Nintedanib combined with or without Dextromethorphan for the treatment of IPF, with FVC as the primary efficacy endpoint to evaluate its effectivenes.
- Trial name
- NCT07583589
- Testing
- Nintedanib,Dextromethorphan
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Reumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder)
Radiologic Features of Rheumatoid Arthritis Interstitial Lung Disease at Chest High Resolution Computed Tomography
Lung involvement is one of the most frequent extra articular involvements of rheumatoid arthritis (RA). RA related lung involvement can affect parenchyma, airway, vascular tree and serosa.
- Conditions
- Reumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), Idiopathic Pulmonary Fibrosis (IPF), Connective Tissue Disease (CTD)
- Trial name
- NCT07174102
- Testing
- High resolution computed tomography
- Where
- 5 sites in Czechia, Italy
- Volunteers
- 500 people
- Sponsor
- Azienda Unita Sanitaria Locale di Piacenza
Idiopathic Pulmonary Fibrosis
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for…
- Trial name
- STRIVE II (NCT07674745)
- Testing
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Alabama at Birmingham
Idiopathic Pulmonary Fibrosis
Cohort of IPF Patients Experiencing an Exacerbation
Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years.
- Trial name
- NCT04442711
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
- Trial name
- AF-BMC (NCT07332117)
- Testing
- No Interventions, No intervention
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust